MedTrace Logo

Treatment of ACuTe Coronary Syndromes With Low-dose colchICine

NCT06215989 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6574

Last updated 2024-10-30

No results posted yet for this study

Summary

This trial is designed to evaluate whether low-dose colchicine, in addition to standard treatment recommended by guidelines, further reduces the risk of major adverse cardiovascular events in patients with acute coronary syndromes (ACS) through a prospective, randomized, double-blind, placebo-controlled clinical trial.

Conditions

  • Acute Coronary Syndrome
  • Unstable Angina
  • ST Elevation Myocardial Infarction
  • Non ST Segment Elevation Myocardial Infarction
  • Colchicine

Interventions

DRUG

Colchicine Pill

Colchicine 0.5mg once daily will be given on the basis of standard treatment of ACS recommended by guidelines

DRUG

Placebo

Placebo one tablet once daily will be given on the basis of standard treatment of ACS recommended by guidelines

Sponsors & Collaborators

  • Beijing Anzhen Hospital

    lead OTHER

Principal Investigators

  • Yujie Zhou, PhD, MD · Beijing Anzhen Hospital

  • Xiaoli Liu, PhD, MD · Beijing Anzhen Hospital

  • Xiaoteng Ma, MD · Beijing Anzhen Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-02
Primary Completion
2027-02-28
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06215989 on ClinicalTrials.gov